← 產業報告目錄
Influenza (Flu) Antiviral Drugs Industry Research Report 2026
出版商 APO Research產業別 Healthcare & Life Sciences出版日期 2026-01-02頁數 149報告編號 APO-23e654ebd0
授權報價
| Single User | $2,950 USD |
| Multi User | $4,430 USD |
| Enterprise | $5,900 USD |
報告摘要
The global Influenza (Flu) Antiviral Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Influenza (Flu) Antiviral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Influenza (Flu) Antiviral Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
The Asia Pacific market for Influenza (Flu) Antiviral Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Influenza (Flu) Antiviral Drugs include Allergan, Aurobindo Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Bristol-Myers-Squibb, Cipla, F. Hoffmann-La Roche, Gilead Sciences and GlaxoSmithKline (GSK), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Influenza (Flu) Antiviral Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Influenza (Flu) Antiviral Drugs Market by Company
Allergan
Aurobindo Pharma
Boehringer Ingelheim
Bristol-Myers Squibb
Bristol-Myers-Squibb
Cipla
F. Hoffmann-La Roche
Gilead Sciences
GlaxoSmithKline (GSK)
Merck & Co. (MSD)
Novo Nordisk
Teva Pharmaceutical Industries
AstraZeneca
AbbVie
Amgen
Bayer
Pfizer
Eli Lilly
Roche
Mylan
Novartis
Johnson & Johnson
Sanofi
Teva
Takeda
Influenza (Flu) Antiviral Drugs Segment by Type
Neuraminidase Inhibitors
Reverse Transcriptase Inhibitors
Broad-spectrum Antiviral Drugs
Protein Inhibitors
Penetration and Dehulling Inhibitors
DNA Polymerase Inhibitors
Influenza (Flu) Antiviral Drugs Segment by Application
Clinic
Hospital
Household
Others
Influenza (Flu) Antiviral Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza (Flu) Antiviral Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Influenza (Flu) Antiviral Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza (Flu) Antiviral Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Influenza (Flu) Antiviral Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Influenza (Flu) Antiviral Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Influenza (Flu) Antiviral Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
目錄 Table of Contents
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Influenza (Flu) Antiviral Drugs Market Size (2021-2032)
2.2.2 Global Influenza (Flu) Antiviral Drugs Sales (2021-2032)
2.2.3 Global Influenza (Flu) Antiviral Drugs Market Average Price (2021-2032)
2.3 Influenza (Flu) Antiviral Drugs by Type
2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
2.3.2 Neuraminidase Inhibitors
2.3.3 Reverse Transcriptase Inhibitors
2.3.4 Broad-spectrum Antiviral Drugs
2.3.5 Protein Inhibitors
2.3.6 Penetration and Dehulling Inhibitors
2.3.7 DNA Polymerase Inhibitors
2.4 Influenza (Flu) Antiviral Drugs by Application
2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
2.4.2 Clinic
2.4.3 Hospital
2.4.4 Household
2.4.5 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global Influenza (Flu) Antiviral Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
3.2 Global Influenza (Flu) Antiviral Drugs Sales (K Units) of Manufacturers (2021-2026)
3.3 Global Influenza (Flu) Antiviral Drugs Revenue of Manufacturers (2021-2026)
3.4 Global Influenza (Flu) Antiviral Drugs Average Price by Manufacturers (2021-2026)
3.5 Global Influenza (Flu) Antiviral Drugs Industry Ranking, 2024 VS 2025 VS 2026
3.6 Global Manufacturers of Influenza (Flu) Antiviral Drugs, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Influenza (Flu) Antiviral Drugs, Product Type & Application
3.8 Global Manufacturers of Influenza (Flu) Antiviral Drugs, Established Date
3.9 Global Influenza (Flu) Antiviral Drugs Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Allergan
4.1.1 Allergan Company Information
4.1.2 Allergan Business Overview
4.1.3 Allergan Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.1.4 Allergan Influenza (Flu) Antiviral Drugs Product Portfolio
4.1.5 Allergan Recent Developments
4.2 Aurobindo Pharma
4.2.1 Aurobindo Pharma Company Information
4.2.2 Aurobindo Pharma Business Overview
4.2.3 Aurobindo Pharma Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.2.4 Aurobindo Pharma Influenza (Flu) Antiviral Drugs Product Portfolio
4.2.5 Aurobindo Pharma Recent Developments
4.3 Boehringer Ingelheim
4.3.1 Boehringer Ingelheim Company Information
4.3.2 Boehringer Ingelheim Business Overview
4.3.3 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.3.4 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product Portfolio
4.3.5 Boehringer Ingelheim Recent Developments
4.4 Bristol-Myers Squibb
4.4.1 Bristol-Myers Squibb Company Information
4.4.2 Bristol-Myers Squibb Business Overview
4.4.3 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.4.4 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
4.4.5 Bristol-Myers Squibb Recent Developments
4.5 Bristol-Myers-Squibb
4.5.1 Bristol-Myers-Squibb Company Information
4.5.2 Bristol-Myers-Squibb Business Overview
4.5.3 Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.5.4 Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
4.5.5 Bristol-Myers-Squibb Recent Developments
4.6 Cipla
4.6.1 Cipla Company Information
4.6.2 Cipla Business Overview
4.6.3 Cipla Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.6.4 Cipla Influenza (Flu) Antiviral Drugs Product Portfolio
4.6.5 Cipla Recent Developments
4.7 F. Hoffmann-La Roche
4.7.1 F. Hoffmann-La Roche Company Information
4.7.2 F. Hoffmann-La Roche Business Overview
4.7.3 F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.7.4 F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Product Portfolio
4.7.5 F. Hoffmann-La Roche Recent Developments
4.8 Gilead Sciences
4.8.1 Gilead Sciences Company Information
4.8.2 Gilead Sciences Business Overview
4.8.3 Gilead Sciences Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.8.4 Gilead Sciences Influenza (Flu) Antiviral Drugs Product Portfolio
4.8.5 Gilead Sciences Recent Developments
4.9 GlaxoSmithKline (GSK)
4.9.1 GlaxoSmithKline (GSK) Company Information
4.9.2 GlaxoSmithKline (GSK) Business Overview
4.9.3 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.9.4 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product Portfolio
4.9.5 GlaxoSmithKline (GSK) Recent Developments
4.10 Merck & Co. (MSD)
4.10.1 Merck & Co. (MSD) Company Information
4.10.2 Merck & Co. (MSD) Business Overview
4.10.3 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.10.4 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product Portfolio
4.10.5 Merck & Co. (MSD) Recent Developments
4.11 Novo Nordisk
4.11.1 Novo Nordisk Company Information
4.11.2 Novo Nordisk Business Overview
4.11.3 Novo Nordisk Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.11.4 Novo Nordisk Influenza (Flu) Antiviral Drugs Product Portfolio
4.11.5 Novo Nordisk Recent Developments
4.12 Teva Pharmaceutical Industries
4.12.1 Teva Pharmaceutical Industries Company Information
4.12.2 Teva Pharmaceutical Industries Business Overview
4.12.3 Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.12.4 Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Product Portfolio
4.12.5 Teva Pharmaceutical Industries Recent Developments
4.13 AstraZeneca
4.13.1 AstraZeneca Company Information
4.13.2 AstraZeneca Business Overview
4.13.3 AstraZeneca Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.13.4 AstraZeneca Influenza (Flu) Antiviral Drugs Product Portfolio
4.13.5 AstraZeneca Recent Developments
4.14 AbbVie
4.14.1 AbbVie Company Information
4.14.2 AbbVie Business Overview
4.14.3 AbbVie Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.14.4 AbbVie Influenza (Flu) Antiviral Drugs Product Portfolio
4.14.5 AbbVie Recent Developments
4.15 Amgen
4.15.1 Amgen Company Information
4.15.2 Amgen Business Overview
4.15.3 Amgen Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.15.4 Amgen Influenza (Flu) Antiviral Drugs Product Portfolio
4.15.5 Amgen Recent Developments
4.16 Bayer
4.16.1 Bayer Company Information
4.16.2 Bayer Business Overview
4.16.3 Bayer Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.16.4 Bayer Influenza (Flu) Antiviral Drugs Product Portfolio
4.16.5 Bayer Recent Developments
4.17 Pfizer
4.17.1 Pfizer Company Information
4.17.2 Pfizer Business Overview
4.17.3 Pfizer Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.17.4 Pfizer Influenza (Flu) Antiviral Drugs Product Portfolio
4.17.5 Pfizer Recent Developments
4.18 Eli Lilly
4.18.1 Eli Lilly Company Information
4.18.2 Eli Lilly Business Overview
4.18.3 Eli Lilly Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.18.4 Eli Lilly Influenza (Flu) Antiviral Drugs Product Portfolio
4.18.5 Eli Lilly Recent Developments
4.19 Roche
4.19.1 Roche Company Information
4.19.2 Roche Business Overview
4.19.3 Roche Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.19.4 Roche Influenza (Flu) Antiviral Drugs Product Portfolio
4.19.5 Roche Recent Developments
4.20 Mylan
4.20.1 Mylan Company Information
4.20.2 Mylan Business Overview
4.20.3 Mylan Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.20.4 Mylan Influenza (Flu) Antiviral Drugs Product Portfolio
4.20.5 Mylan Recent Developments
4.21 Novartis
4.21.1 Novartis Company Information
4.21.2 Novartis Business Overview
4.21.3 Novartis Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.21.4 Novartis Influenza (Flu) Antiviral Drugs Product Portfolio
4.21.5 Novartis Recent Developments
4.22 Johnson & Johnson
4.22.1 Johnson & Johnson Company Information
4.22.2 Johnson & Johnson Business Overview
4.22.3 Johnson & Johnson Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.22.4 Johnson & Johnson Influenza (Flu) Antiviral Drugs Product Portfolio
4.22.5 Johnson & Johnson Recent Developments
4.23 Sanofi
4.23.1 Sanofi Company Information
4.23.2 Sanofi Business Overview
4.23.3 Sanofi Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.23.4 Sanofi Influenza (Flu) Antiviral Drugs Product Portfolio
4.23.5 Sanofi Recent Developments
4.24 Teva
4.24.1 Teva Company Information
4.24.2 Teva Business Overview
4.24.3 Teva Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.24.4 Teva Influenza (Flu) Antiviral Drugs Product Portfolio
4.24.5 Teva Recent Developments
4.25 Takeda
4.25.1 Takeda Company Information
4.25.2 Takeda Business Overview
4.25.3 Takeda Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
4.25.4 Takeda Influenza (Flu) Antiviral Drugs Product Portfolio
4.25.5 Takeda Recent Developments
5 Global Influenza (Flu) Antiviral Drugs Market Scenario by Region
5.1 Global Influenza (Flu) Antiviral Drugs Market Size by Region: 2021 VS 2025 VS 2032
5.2 Global Influenza (Flu) Antiviral Drugs Sales by Region: 2021-2032
5.2.1 Global Influenza (Flu) Antiviral Drugs Sales by Region: 2021-2026
5.2.2 Global Influenza (Flu) Antiviral Drugs Sales by Region: 2027-2032
5.3 Global Influenza (Flu) Antiviral Drugs Revenue by Region: 2021-2032
5.3.1 Global Influenza (Flu) Antiviral Drugs Revenue by Region: 2021-2026
5.3.2 Global Influenza (Flu) Antiviral Drugs Revenue by Region: 2027-2032
5.4 North America Influenza (Flu) Antiviral Drugs Market Facts & Figures by Country
5.4.1 North America Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.4.2 North America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
5.4.3 North America Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2032)
5.4.4 United States
5.4.5 Canada
5.5 Europe Influenza (Flu) Antiviral Drugs Market Facts & Figures by Country
5.5.1 Europe Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.5.2 Europe Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
5.5.3 Europe Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2032)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.5.9 Nordic Countries
5.6 Asia Pacific Influenza (Flu) Antiviral Drugs Market Facts & Figures by Country
5.6.1 Asia Pacific Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.6.2 Asia Pacific Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
5.6.3 Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2032)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Influenza (Flu) Antiviral Drugs Market Facts & Figures by Country
5.7.1 South America Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.7.2 South America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
5.7.3 South America Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2032)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.7.7 Colombia
5.8 Middle East and Africa Influenza (Flu) Antiviral Drugs Market Facts & Figures by Country
5.8.1 Middle East and Africa Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.8.2 Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
5.8.3 Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2032)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Influenza (Flu) Antiviral Drugs Sales by Type (2021-2032)
6.1.1 Global Influenza (Flu) Antiviral Drugs Sales by Type (2021-2032) & (K Units)
6.1.2 Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2021-2032)
6.2 Global Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2032)
6.2.1 Global Influenza (Flu) Antiviral Drugs Sales by Type (2021-2032) & (US$ Million)
6.2.2 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2021-2032)
6.3 Global Influenza (Flu) Antiviral Drugs Price by Type (2021-2032)
7 Segment by Application
7.1 Global Influenza (Flu) Antiviral Drugs Sales by Application (2021-2032)
7.1.1 Global Influenza (Flu) Antiviral Drugs Sales by Application (2021-2032) & (K Units)
7.1.2 Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2021-2032)
7.2 Global Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2032)
7.2.1 Global Influenza (Flu) Antiviral Drugs Sales by Application (2021-2032) & (US$ Million)
7.2.2 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2021-2032)
7.3 Global Influenza (Flu) Antiviral Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Influenza (Flu) Antiviral Drugs Value Chain Analysis
8.1.1 Influenza (Flu) Antiviral Drugs Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Influenza (Flu) Antiviral Drugs Production Mode & Process
8.2 Influenza (Flu) Antiviral Drugs Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Influenza (Flu) Antiviral Drugs Distributors
8.2.3 Influenza (Flu) Antiviral Drugs Customers
9 Global Influenza (Flu) Antiviral Drugs Analyzing Market Dynamics
9.1 Influenza (Flu) Antiviral Drugs Industry Trends
9.2 Influenza (Flu) Antiviral Drugs Industry Drivers
9.3 Influenza (Flu) Antiviral Drugs Industry Opportunities and Challenges
9.4 Influenza (Flu) Antiviral Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Influenza (Flu) Antiviral Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Influenza (Flu) Antiviral Drugs Sales (K Units) of Manufacturers (2021-2026)
Table 7. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Influenza (Flu) Antiviral Drugs Revenue of Manufacturers (2021-2026)
Table 9. Global Influenza (Flu) Antiviral Drugs Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Influenza (Flu) Antiviral Drugs Average Price (US$/Unit) of Manufacturers (2021-2026)
Table 11. Global Influenza (Flu) Antiviral Drugs Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Influenza (Flu) Antiviral Drugs, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Influenza (Flu) Antiviral Drugs, Product Type & Application
Table 14. Global Influenza (Flu) Antiviral Drugs Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Influenza (Flu) Antiviral Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Allergan Company Information
Table 19. Allergan Business Overview
Table 20. Allergan Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 21. Allergan Influenza (Flu) Antiviral Drugs Product Portfolio
Table 22. Allergan Recent Developments
Table 23. Aurobindo Pharma Company Information
Table 24. Aurobindo Pharma Business Overview
Table 25. Aurobindo Pharma Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 26. Aurobindo Pharma Influenza (Flu) Antiviral Drugs Product Portfolio
Table 27. Aurobindo Pharma Recent Developments
Table 28. Boehringer Ingelheim Company Information
Table 29. Boehringer Ingelheim Business Overview
Table 30. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 31. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product Portfolio
Table 32. Boehringer Ingelheim Recent Developments
Table 33. Bristol-Myers Squibb Company Information
Table 34. Bristol-Myers Squibb Business Overview
Table 35. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 36. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
Table 37. Bristol-Myers Squibb Recent Developments
Table 38. Bristol-Myers-Squibb Company Information
Table 39. Bristol-Myers-Squibb Business Overview
Table 40. Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 41. Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
Table 42. Bristol-Myers-Squibb Recent Developments
Table 43. Cipla Company Information
Table 44. Cipla Business Overview
Table 45. Cipla Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 46. Cipla Influenza (Flu) Antiviral Drugs Product Portfolio
Table 47. Cipla Recent Developments
Table 48. F. Hoffmann-La Roche Company Information
Table 49. F. Hoffmann-La Roche Business Overview
Table 50. F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 51. F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Product Portfolio
Table 52. F. Hoffmann-La Roche Recent Developments
Table 53. Gilead Sciences Company Information
Table 54. Gilead Sciences Business Overview
Table 55. Gilead Sciences Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 56. Gilead Sciences Influenza (Flu) Antiviral Drugs Product Portfolio
Table 57. Gilead Sciences Recent Developments
Table 58. GlaxoSmithKline (GSK) Company Information
Table 59. GlaxoSmithKline (GSK) Business Overview
Table 60. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 61. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product Portfolio
Table 62. GlaxoSmithKline (GSK) Recent Developments
Table 63. Merck & Co. (MSD) Company Information
Table 64. Merck & Co. (MSD) Business Overview
Table 65. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product Portfolio
Table 67. Merck & Co. (MSD) Recent Developments
Table 68. Novo Nordisk Company Information
Table 69. Novo Nordisk Business Overview
Table 70. Novo Nordisk Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Novo Nordisk Influenza (Flu) Antiviral Drugs Product Portfolio
Table 72. Novo Nordisk Recent Developments
Table 73. Teva Pharmaceutical Industries Company Information
Table 74. Teva Pharmaceutical Industries Business Overview
Table 75. Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Product Portfolio
Table 77. Teva Pharmaceutical Industries Recent Developments
Table 78. AstraZeneca Company Information
Table 79. AstraZeneca Business Overview
Table 80. AstraZeneca Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. AstraZeneca Influenza (Flu) Antiviral Drugs Product Portfolio
Table 82. AstraZeneca Recent Developments
Table 83. AbbVie Company Information
Table 84. AbbVie Business Overview
Table 85. AbbVie Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. AbbVie Influenza (Flu) Antiviral Drugs Product Portfolio
Table 87. AbbVie Recent Developments
Table 88. Amgen Company Information
Table 89. Amgen Business Overview
Table 90. Amgen Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Amgen Influenza (Flu) Antiviral Drugs Product Portfolio
Table 92. Amgen Recent Developments
Table 93. Bayer Company Information
Table 94. Bayer Business Overview
Table 95. Bayer Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Bayer Influenza (Flu) Antiviral Drugs Product Portfolio
Table 97. Bayer Recent Developments
Table 98. Pfizer Company Information
Table 99. Pfizer Business Overview
Table 100. Pfizer Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Pfizer Influenza (Flu) Antiviral Drugs Product Portfolio
Table 102. Pfizer Recent Developments
Table 103. Eli Lilly Company Information
Table 104. Eli Lilly Business Overview
Table 105. Eli Lilly Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Eli Lilly Influenza (Flu) Antiviral Drugs Product Portfolio
Table 107. Eli Lilly Recent Developments
Table 108. Roche Company Information
Table 109. Roche Business Overview
Table 110. Roche Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Roche Influenza (Flu) Antiviral Drugs Product Portfolio
Table 112. Roche Recent Developments
Table 113. Mylan Company Information
Table 114. Mylan Business Overview
Table 115. Mylan Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Mylan Influenza (Flu) Antiviral Drugs Product Portfolio
Table 117. Mylan Recent Developments
Table 118. Novartis Company Information
Table 119. Novartis Business Overview
Table 120. Novartis Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Novartis Influenza (Flu) Antiviral Drugs Product Portfolio
Table 122. Novartis Recent Developments
Table 123. Johnson & Johnson Company Information
Table 124. Johnson & Johnson Business Overview
Table 125. Johnson & Johnson Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Johnson & Johnson Influenza (Flu) Antiviral Drugs Product Portfolio
Table 127. Johnson & Johnson Recent Developments
Table 128. Sanofi Company Information
Table 129. Sanofi Business Overview
Table 130. Sanofi Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Sanofi Influenza (Flu) Antiviral Drugs Product Portfolio
Table 132. Sanofi Recent Developments
Table 133. Teva Company Information
Table 134. Teva Business Overview
Table 135. Teva Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Teva Influenza (Flu) Antiviral Drugs Product Portfolio
Table 137. Teva Recent Developments
Table 138. Takeda Company Information
Table 139. Takeda Business Overview
Table 140. Takeda Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Takeda Influenza (Flu) Antiviral Drugs Product Portfolio
Table 142. Takeda Recent Developments
Table 143. Global Influenza (Flu) Antiviral Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 144. Global Influenza (Flu) Antiviral Drugs Sales by Region (2021-2026) & (K Units)
Table 145. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Region (2021-2026)
Table 146. Global Influenza (Flu) Antiviral Drugs Sales by Region (2027-2032) & (K Units)
Table 147. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Region (2027-2032)
Table 148. Global Influenza (Flu) Antiviral Drugs Revenue by Region (2021-2026) & (US$ Million)
Table 149. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2021-2026)
Table 150. Global Influenza (Flu) Antiviral Drugs Revenue by Region (2027-2032) & (US$ Million)
Table 151. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2027-2032)
Table 152. North America Influenza (Flu) Antiviral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 153. North America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units)
Table 154. North America Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units)
Table 155. North America Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 156. North America Influenza (Flu) Antiviral Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 157. Europe Influenza (Flu) Antiviral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 158. Europe Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units)
Table 159. Europe Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units)
Table 160. Europe Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 161. Europe Influenza (Flu) Antiviral Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 162. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 163. Asia Pacific Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units)
Table 164. Asia Pacific Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units)
Table 165. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 166. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 167. South America Influenza (Flu) Antiviral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 168. South America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units)
Table 169. South America Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units)
Table 170. South America Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 171. South America Influenza (Flu) Antiviral Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 172. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 173. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units)
Table 174. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units)
Table 175. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 176. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 177. Global Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units)
Table 178. Global Influenza (Flu) Antiviral Drugs Sales by Type (2027-2032) & (K Units)
Table 179. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2021-2026)
Table 180. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2027-2032)
Table 181. Global Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2026) & (US$ Million)
Table 182. Global Influenza (Flu) Antiviral Drugs Revenue by Type (2027-2032) & (US$ Million)
Table 183. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2021-2026)
Table 184. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2027-2032)
Table 185. Global Influenza (Flu) Antiviral Drugs Price by Type (2021-2026) & (US$/Unit)
Table 186. Global Influenza (Flu) Antiviral Drugs Price by Type (2027-2032) & (US$/Unit)
Table 187. Global Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units)
Table 188. Global Influenza (Flu) Antiviral Drugs Sales by Application (2027-2032) & (K Units)
Table 189. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2021-2026)
Table 190. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2027-2032)
Table 191. Global Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2026) & (US$ Million)
Table 192. Global Influenza (Flu) Antiviral Drugs Revenue by Application (2027-2032) & (US$ Million)
Table 193. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2021-2026)
Table 194. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2027-2032)
Table 195. Global Influenza (Flu) Antiviral Drugs Price by Application (2021-2026) & (US$/Unit)
Table 196. Global Influenza (Flu) Antiviral Drugs Price by Application (2027-2032) & (US$/Unit)
Table 197. Key Raw Materials
Table 198. Raw Materials Key Suppliers
Table 199. Influenza (Flu) Antiviral Drugs Distributors List
Table 200. Influenza (Flu) Antiviral Drugs Customers List
Table 201. Influenza (Flu) Antiviral Drugs Industry Trends
Table 202. Influenza (Flu) Antiviral Drugs Industry Drivers
Table 203. Influenza (Flu) Antiviral Drugs Industry Restraints
Table 204. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Influenza (Flu) Antiviral Drugs Product Image
Figure 5. Global Influenza (Flu) Antiviral Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Influenza (Flu) Antiviral Drugs Market Size (2021-2032) & (US$ Million)
Figure 7. Global Influenza (Flu) Antiviral Drugs Sales (2021-2032) & (K Units)
Figure 8. Global Influenza (Flu) Antiviral Drugs Average Price (US$/Unit) & (2021-2032)
Figure 9. Neuraminidase Inhibitors Product Image
Figure 10. Reverse Transcriptase Inhibitors Product Image
Figure 11. Broad-spectrum Antiviral Drugs Product Image
Figure 12. Protein Inhibitors Product Image
Figure 13. Penetration and Dehulling Inhibitors Product Image
Figure 14. DNA Polymerase Inhibitors Product Image
Figure 15. Clinic Product Image
Figure 16. Hospital Product Image
Figure 17. Household Product Image
Figure 18. Others Product Image
Figure 19. Global Influenza (Flu) Antiviral Drugs Revenue Share by Manufacturers in 2025
Figure 20. Global Manufacturers of Influenza (Flu) Antiviral Drugs, Manufacturing Sites & Headquarters
Figure 21. Global Top 5 and 10 Influenza (Flu) Antiviral Drugs Players Market Share by Revenue in 2025
Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 23. Global Influenza (Flu) Antiviral Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 24. Global Influenza (Flu) Antiviral Drugs Sales by Region in 2025
Figure 25. Global Influenza (Flu) Antiviral Drugs Revenue by Region in 2025
Figure 26. North America Influenza (Flu) Antiviral Drugs Market Size by Country in 2025
Figure 27. North America Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2032)
Figure 28. North America Influenza (Flu) Antiviral Drugs Revenue Market Share by Country (2021-2032)
Figure 29. United States Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 30. Canada Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 31. Europe Influenza (Flu) Antiviral Drugs Market Size by Country in 2025
Figure 32. Europe Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2032)
Figure 33. Europe Influenza (Flu) Antiviral Drugs Revenue Market Share by Country (2021-2032)
Figure 34. Germany Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. France Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. U.K. Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 37. Italy Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 38. Netherlands Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. Nordic Countries Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. Asia Pacific Influenza (Flu) Antiviral Drugs Market Size by Country in 2025
Figure 41. Asia Pacific Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2032)
Figure 42. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue Market Share by Country (2021-2032)
Figure 43. China Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 44. Japan Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 45. South Korea Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 46. India Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 47. Australia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 48. China Taiwan Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 49. Southeast Asia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. Southeast Asia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. South America Influenza (Flu) Antiviral Drugs Market Size by Country in 2025
Figure 52. South America Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2032)
Figure 53. South America Influenza (Flu) Antiviral Drugs Revenue Market Share by Country (2021-2032)
Figure 54. Mexico Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 55. Brazil Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 56. Argentina Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 57. Colombia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 58. Middle East and Africa Influenza (Flu) Antiviral Drugs Market Size by Country in 2025
Figure 59. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2032)
Figure 60. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue Market Share by Country (2021-2032)
Figure 61. Turkey Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 62. Saudi Arabia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 63. UAE Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 64. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2021-2032)
Figure 65. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2021-2032)
Figure 66. Global Influenza (Flu) Antiviral Drugs Price (US$/Unit) by Type (2021-2032)
Figure 67. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2021-2032)
Figure 68. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2021-2032)
Figure 69. Global Influenza (Flu) Antiviral Drugs Price (US$/Unit) by Application (2021-2032)
Figure 70. Influenza (Flu) Antiviral Drugs Value Chain
Figure 71. Influenza (Flu) Antiviral Drugs Production Mode & Process
Figure 72. Direct Comparison with Distribution Share
Figure 73. Distributors Profiles
Figure 74. Influenza (Flu) Antiviral Drugs Industry Opportunities and Challenges
提及公司
AllerganAurobindo PharmaBoehringer IngelheimBristol-Myers SquibbBristol-Myers-SquibbCiplaF. Hoffmann-La RocheGilead SciencesGlaxoSmithKline (GSK)Merck & Co. (MSD)Novo NordiskTeva Pharmaceutical IndustriesAstraZenecaAbbVieAmgenBayerPfizerEli LillyRocheMylanNovartisJohnson & JohnsonSanofiTevaTakeda
量子訊息有限公司為 APO Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們